Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
AI Summary
Axiom Biosciences, a U.S. biotech firm, plans to list in Hong Kong in 2027 before a secondary U.S. listing in 2029, citing access to sophisticated biotech investors and proximity to Asian partners. The company’s CEO noted that Hong Kong’s stricter listing standards reflect a mature biotech ecosystem, and that the city’s biotech index has outperformed U.S. indexes since early 2025. The move highlights a growing trend of biotech firms turning to Hong Kong amid a tougher fundraising environment and expanding investor base.